Two out of three patients who stop semaglutide after losing weight regain most of it within a year. That comes from the STEP 1 Extension trial published in 2022. Not a worst-case figure. That's the average.
I bring this up with patients before we even talk dosing. Not to talk anyone out of it, because these are genuinely among the most effective tools we have for obesity, but because it changes what they're agreeing to. The medication works while they're on it. Once they stop, the biology that was driving the weight gain is still there, unchanged.
That's where the weight comes back from.
Why the Weight Returns
GLP-1 receptor agonists suppress appetite through pathways in the brain and gut. People feel full faster, stay full longer, eat less. It doesn't feel like restriction because the drive to eat more just isn't there the way it used to be.
Stop the medication and those signals fade as the drug clears. It's not immediate for everyone, but it comes. Hunger returns. Portions that felt fine start feeling small. Food becomes more rewarding again. Most patients don't clock it happening. They just notice a few weeks later that they're eating roughly what they used to eat, and the weight is moving in the wrong direction.
I've had patients insist they're eating the same as they were on the medication. Almost every time, that's not quite right. What's actually happening is small increases, nothing dramatic, nothing they'd notice day to day, that compound over weeks. The appetite suppression had been doing more work than they realized.
Nothing about the underlying biology was corrected. It was being managed. There's a real difference.
The Trial Numbers
The trials are pretty consistent here. STEP 1 Extension found that participants who stopped semaglutide had regained about 66% of their lost weight within a year. These were people who had lost an average of 17.3% of body weight to start, so the regain was meaningful in real terms. Tirzepatide data from SURMOUNT-4 tells a similar story: those who discontinued regained roughly 14% of body weight over 52 weeks, while people who stayed on treatment continued holding or improving their results. Zoom out to observational data and the picture is the same: without ongoing treatment or serious structured support, most patients trend back toward where they started over a few years. Not every patient. But enough that it's the pattern you plan around, not the exception.
How It Usually Unfolds
It doesn't collapse overnight. There's a sequence to it that's recognizable once you've seen it a few times.
Hunger starts to return, often more quickly than people expect. Portions that felt normal on the medication begin to feel small again.
This is where most of the regain starts. Intake increases gradually, often without conscious awareness. Weight usually starts trending up during this period.
Regain continues but tends to slow. Some patients stabilize partway if they've built strong habits during treatment. Others continue steadily back toward their previous weight.
Outcomes start to split. A minority maintain most of their loss, usually those who made significant behavioral changes. The majority regain a substantial portion.
Not Everyone Regains Everything
That said, some patients stop and keep the weight off. It happens.
The ones who do tend to have used the time on treatment to actually build something: eating habits that hold without pharmacologic appetite suppression backing them up. Not a specific diet. More like structure they can run on autopilot.
They're not the majority in the data, but they exist. One thing that consistently surprises people is that the patients who lost the most weight on the drug aren't necessarily the ones who maintain best after stopping. Big responders don't automatically hold their results better than moderate responders. Whatever predicts response to the medication doesn't seem to be the same thing that predicts durability after you stop it.
Slowing the Rebound
Regain after stopping seems to happen regardless, but how fast and how much varies. A few things appear to matter.
Tapering rather than stopping cold tends to make the first few months easier. The appetite rebound is less sharp. Long-term outcomes don't look dramatically different, but the transition is smoother and patients are more likely to stay on track during it. Having real eating habits in place before stopping helps too. Not a specific protocol, just some structure that runs without active management. Patients who built that during treatment do better than the ones who leaned entirely on the medication.
Some clinicians are also moving toward dose reduction or agent switching instead of stopping entirely. Step down to a lower maintenance dose, or try a different mechanism. It's not always covered or accessible, but when it's an option it can take some of the edge off the rebound.
Reasons People Stop
Cost is the most common reason I see. Insurance coverage for these medications is inconsistent, manufacturer programs help some patients more than others, and when coverage ends people stop. Side effects push some patients off, usually in the early weeks, usually manageable with slower titration, but not always. And then there's the group that stopped because they hit their goal weight and figured the job was done.
That last group is the one I think about most. Hitting a goal weight on a GLP-1 doesn't mean the underlying condition resolved. It means it's being controlled. Blood pressure medications work the same way. Nobody expects to take them for six months and then stop. If you stop and the pressure goes back up, that's not the drug failing. That's just what the condition does without treatment. GLP-1s are the same deal, and I think patients are better off knowing that going in rather than being surprised by it six months after they stop.
The Conversation I Have First
The regain isn't a character flaw. Patients who regain weight after stopping aren't failing at something. They're experiencing what the biology does when treatment is removed. Obesity has persistent drivers that don't reset because you spent a year losing weight on medication. The medication was holding them down. Take it away and they push back up.
GLP-1s work well. They just work while you're taking them. For most people, that's the frame: not a course of treatment with an endpoint, but ongoing management of a chronic condition. Whether that's acceptable depends on a lot of factors specific to each patient, access, cost, side effect profile, personal goals. Some patients stop and do fine. Many don't.
What I try to make sure is that people understand that before they make the decision, not after they've already started regaining and are trying to figure out what went wrong.
